Assenagon Asset Management
NVCR icon

Assenagon Asset Management’s NovoCure NVCR Stock Holding History

Assenagon Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,451
Closed -$208K – 1423
2023
Q1 		$208K Hold
3,451
– – ﹤0.01% 1357
2022
Q4 		$253K Hold
3,451
– – ﹤0.01% 1283
2022
Q3 		$262K Buy
+3,451
New +$269K ﹤0.01% 1236

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Assenagon Asset Management's NVCR Position: Q2 2023 in Review

Assenagon Asset Management sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 3,451 shares — an estimated $208K sold.

Assenagon Asset Management first reported a position in NVCR in Q3 2022 and held it in 3 quarters. The position peaked at $262K in Q3 2022. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

  • Assenagon Asset Management reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
  • Assenagon Asset Management sold 3,451 NovoCure shares in Q2 2023, an estimated $208K.
  • Assenagon Asset Management first reported a position in NovoCure in Q3 2022 and held it in 3 quarters.
  • Assenagon Asset Management's NovoCure position peaked at $262K in Q3 2022.
  • 267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Assenagon Asset Management's 13F filing for Q2 2023, filed 25 Jul 2023.